Kuria awarded a Phase I NIH SBIR grant to advance SCO-116 for Fuchs' dystrophy

NIH grant milestone completion supports continued advancement of SCO-116 through IND-enabling development

Kuria announces that its NIH SBIR grant has received matching funds from the Arkansas Economic Development Commission. Funds will amplify the impact of the federal research dollars.

Kuria Therapeutics, a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic disease, will be holding meetings with investors and other parties during the 44th Annual J.P. Morgan Healthcare Conference, January 11-15 2026, in San Francisco, California. Kuria's Chief Executive Officer, Dr. Keith Ward, will be holding one-on-one meetings during the conference to discuss the latest company and data updates for Kuria's lead program transforming treatm

Kuria granted an SBIR award to fund IND-enabling toxicology studies for Fuchs' dystrophy.

- Kuria to present positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease Kuria...

- Kuria team to present potency, selectivity, and positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and...

- Kuria's Chief Executive Officer Dr. Keith Ward to present company overview to premiere venture forum in the Southeast Kuria...

- Kuria's Chief Executive Officer and Chief Development Officer to share ophthalmic program updates and present corporate overview Kuria...

- Chief Development Officer Dave Flory to present corporate overview and review Kuria's development plans for diseases of the cornea and...

- Expands development pipeline with planned Phase 2 clinical trial for dry AMD Kuria Therapeutics, a pharmaceutical company developing a...

Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease LITTLE ROCK,...

SCOHIA PHARMA and Kuria Therapeutics Announce Issuance of Key Patent Covering Novel Nrf2 Activator KANAGAWA, Japan & LITTLE ROCK,...

Kuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 Activator - Funds to support ongoing preclinical development...

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2...